8-K: BriaPro Q3 2025: R&D Soars, Losses Mount, Funding Crucial

BriaPro Therapeutics Corp., a BriaCell subsidiary, reported significantly increased R&D expenses and operating losses for Q3 2025, highlighting its critical dependence on future financing to advance its pre-clinical oncology programs.

Summary

• BriaPro Therapeutics Corp., a 2/3 owned subsidiary of BriaCell Therapeutics Corp., filed its unaudited condensed interim consolidated financial statements for the three months ended October 31, 2025.
• The company reported a total operating loss and comprehensive loss of $244,738 for the period, a significant increase from $82,123 in the same period of 2024.
• Research and development expenses surged to $237,501, up from $48,500 in the prior year, primarily due to increased wages and supplies.
• General and administrative expenses slightly decreased to $20,944 from $22,503.
• BriaPro's accumulated deficit grew to $1,425,163 as of October 31, 2025, from $1,180,425 at July 31, 2025.
• The company has negative working capital of $1,403,119 and is entirely dependent on BriaCell Therapeutics Corp. to finance its operations until additional financing is secured.
• Key pre-clinical programs include Bria-TILsRx, PKC inhibitors, and anti-B7-H3 antibodies, with provisional patent applications filed for TILsRx (July 29, 2025) and B7-H3 antibodies (April 10, 2025).
• BriaPro is leveraging artificial intelligence (AI) in collaboration with Receptor.AI for drug candidate selection and optimization of PKC inhibitors.

Sentiment

Score: 3

Explanation: While the company has promising pre-clinical programs and leverages AI, its financial position is extremely weak with minimal cash, increasing losses, and a critical dependence on external financing, casting significant doubt on its going concern ability. The delays in clinical trials due to funding further dampen sentiment.

Positives

• Active research and development programs in immuno-oncology, including Bria-TILsRx, PKC inhibitors, and anti-B7-H3 antibodies.
• Successful design of a battery of antibodies to an important oncology target using in silico modeling, with a provisional patent application filed on May 21, 2024.
• Initial assays for PKC delta inhibitors have shown positive results for inhibition.
• Filed provisional patent applications for its TILsRx platform (July 29, 2025) and novel anti-B7-H3 antibodies (April 10, 2025), with a corresponding PCT international patent for B7-H3 filed in May 2025.
• Leveraging artificial intelligence (AI) in drug discovery, a rapidly growing market segment projected to reach $20.30 billion by 2030.
• Management believes its anti-B7-H3 antibody has superior target-binding potential compared to competitors.
• The quadrivalent Bria-TILsRx platform is a new concept with high potential as a potentially first-in-class drug platform.

Negatives

• Significant increase in total operating loss and comprehensive loss to $244,738 for the three months ended October 31, 2025, from $82,123 in the prior year.
• Accumulated deficit increased to $1,425,163 as of October 31, 2025.
• Negative working capital of $1,403,119 as of October 31, 2025, indicating insufficient current financial resources.
• The company has only $1 in cash and cash equivalents.
• Entirely dependent on BriaCell Therapeutics Corp. to finance operations until additional financing is raised.
• Human clinical studies for Bria-TILsRx and IND enabling studies for anti-B7-H3 antibodies are pending funding.
• The company has a limited operating history and no operating revenues.
• Material uncertainty regarding the company's ability to continue as a going concern.

Risks

• No assurance that BriaPro Shares will ever be listed on any stock exchange, and no current market for them.
• Future sales or issuances of securities will result in substantial dilution to existing shareholders.
• Limited operating history and no operating revenues since incorporation on May 15, 2023.
• Lack of extensive clinical data to support the clinical effectiveness and safety of developmental products.
• Unproven market for product candidates, with assumptions about market existence and expansion potentially being incorrect.
• Anticipated business growth is expected to strain managerial, operational, and technical resources.
• Significant reliance on third parties for manufacturing, pharmaceutical development, marketing, and clinical trials.
• Pre-clinical studies and initial clinical trials are not necessarily predictive of future results, and favorable early results may not be repeated.
• Inability to obtain raw materials or product supply from third-party manufacturers could materially impact the business.
• Must obtain additional capital to continue operations, with no assurance of obtaining adequate financing on reasonable terms.
• Highly dependent on a few key personnel, and the loss of their services could have a material adverse effect on the business.
• Potential conflicts of interest for directors and officers who are also involved with BriaCell Therapeutics Corp.
• No history of earnings or return on investment, and no assurance of future profitability.
• Exposure to increased costs and potential enforcement actions due to existing and proposed changes in laws and regulations affecting public companies.
• Dilution of equity interests from future issuances of securities.
• No independent operating history for the BriaPro Assets, with future cash flow estimates based on combined operations with BriaCell.
• Market perception of early-stage companies may change, affecting value and ability to raise funds.
• No plans to pay dividends for the foreseeable future.
• Operations are subject to governmental laws and regulations, with potential for fines, penalties, and increased compliance costs.
• Exposure to federal, state, and provincial data protection laws and regulations (e.g., HIPAA, HITECH), with potential for significant civil, criminal, and administrative penalties for non-compliance.
• Risk of product liability suits as drug candidates enter clinical trials and commercialization, with no current product liability insurance.
• Reliance on third-party licenses for intellectual property, with uncertainty regarding availability and cost of future licenses.
• Risk of failure to comply with intellectual property or license agreements, potentially leading to termination of licenses.
• Reliance on the Transition Services Agreement with BriaCell, with risks if the agreement is invalid, unenforceable, or terminated.
• BriaCell Therapeutics Corp. as a significant majority shareholder can exercise influence over corporate actions.
• Inflation has the potential to adversely affect the business by increasing overall cost structure.
• Material weaknesses in internal accounting controls, including lack of segregation of duties, inadequate documentation, inconsistent procedures, and insufficient policies.
• Government price controls and other restrictions on pricing, reimbursement, and access to drugs could affect future revenues and profitability.
• Intellectual property litigation risks, including infringement claims and the cost and time associated with litigation.
• Steps taken to protect intellectual property (patents, confidentiality agreements) may be inadequate.
• Need to initiate lawsuits to protect or enforce patents and other intellectual property rights.
• Damage resulting from claims of inadvertent use or disclosure of trade secrets by employees or contractors.
• Risk of generic competition and inadequate patent terms to protect competitive position.
• Operations are subject to human error, potentially leading to significant uninsured losses.
• Difficulty in enforcing judgments and effecting service of process on directors and officers residing outside of Canada.
• Litigation risk in the ordinary course of business.
• Insurance coverage may be subject to limits and exclusions, and may not be adequate or obtainable in the future.
• Negative impact from adverse or inaccurate information posted on social media platforms.

Future Outlook

BriaPro expects to screen several Bria-TILsRx multi-specific binding reagents in vitro and in mouse models over the next year, aiming to select at least one candidate for IND enabling studies. Human clinical studies for Bria-TILsRx are anticipated to begin in the first half of 2027, contingent on securing funding. Concurrently, the company plans to select and optimize novel protein kinase C delta inhibitors, with human clinical studies expected to commence in the second half of 2026. Additionally, anti-B7-H3 antibodies are slated for development as antibody drug conjugates, with IND enabling studies dependent on funding availability.

Management Comments

• The Company expects to incur further losses through to the completion of the research and development of any therapy; the nature of a development stage immune-oncology company requires the raising of financial capital to support its clinical development programs and administrative costs.
• The Company is planning to finance its operations by exploring additional sources of capital and financing, while managing its existing working capital resources.
• BriaPro believes that the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this MD&A should not be unduly relied upon by readers, as actual results may vary.
• BriaPro believes that by partnering with experts in the field it has a competitive advantage to develop selective and potent PKC inhibitors.
• To further develop these assets, BriaPro anticipates raising additional funds for animal studies including efficacy experiments in mice and toxicology/pharmacokinetics studies needed for Investigational New Drug applications.

Industry Context

BriaPro operates in the highly competitive global cancer immunotherapy market, estimated at $115 billion in 2022. The company is also positioned within the rapidly growing AI-driven drug discovery sector, which was valued at $1.5 billion in 2023 and is projected to reach $20.30 billion by 2030, demonstrating a CAGR of 29.7%. BriaPro aims to differentiate itself through its novel quadrivalent Bria-TILsRx platform, specific receptor targeting, and unique PKC delta inhibitors, leveraging AI to enhance drug candidate selection and optimization. Current immunotherapies like bi-specific T cell engagers (BiTEs) such as BLINCYTO and IMDELLTRA are limited by available cancer cell targets, which BriaPro seeks to overcome with AI-driven development of novel binding agents.

Comparison to Industry Standards

• The global cancer immunotherapy market was estimated at $115 billion in 2022, indicating a large addressable market for BriaPro's programs.
• The AI-driven drug discovery market was estimated at USD 1.5 billion in 2023 and is projected to reach USD 20.30 billion by 2030, growing at a CAGR of 29.7%, suggesting BriaPro is operating in a high-growth segment.
• BriaPro's quadrivalent Bria-TILsRx platform is presented as potentially more specific and potent than current bi-specific T cell engagers (BiTEs) like BLINCYTO (for leukemia) and IMDELLTRA (for lung cancer), which are limited by cancer cell targets.
• BriaPro's anti-B7-H3 antibody was designed to have superior target-binding potential compared to an anti-B7-H3 antibody developed and tested in the clinic by others.
• The PKC inhibitor field is noted as stalled due to challenges in isoform-selectivity, where BriaPro believes its partnerships provide a competitive advantage.

Corporate Governance

Related Party Transactions

• BriaPro Therapeutics Corp. owes BriaCell group companies $1,311,743 as of October 31, 2025.
• BriaCell provides certain research and development and head office services to BriaPro for a fixed monthly fee of $20,000 under a Transition Services Agreement.
• For the three months ended October 31, 2025, fixed monthly services expense totaled $60,000 and direct expenses incurred by BriaCell on behalf of BriaPro totaled $130,690, for a total of $190,690.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future capital raises, potential loss of entire investment due to going concern uncertainty, and no current market for BriaPro shares.
• Employees/Consultants: Benefit from the BriaPro Incentive Plan (stock options, RSUs, etc.) but face uncertainty due to the company's financial instability and dependence on BriaCell.
• BriaCell Therapeutics Corp. (Holding Company): Continues to finance BriaPro's operations, with a growing balance owed to it ($1,311,743), indicating increasing financial exposure.
• Creditors: Face increased risk due to the company's negative working capital and going concern uncertainty.
• Patients/Medical Community: Potential future benefit from the development of novel cancer immunotherapies and PKC inhibitors, but progress is contingent on securing substantial funding.

Next Steps

• Screen several Bria-TILsRx multi-specific binding reagents for activity in vitro and in mouse models of cancer over the next year.
• Select at least one Bria-TILsRx candidate to advance into IND enabling studies over the next year.
• Initiate human clinical studies for Bria-TILsRx in the first half of 2027, pending funding.
• Select novel protein kinase C delta inhibitors, optimize structures, and advance to the candidate selection stage.
• Initiate human clinical studies for PKC inhibitors in the second half of 2026.
• Develop anti-B7-H3 antibodies as antibody drug conjugates (ADC), with IND enabling studies to begin when funding is available.
• Expand the number of full-time employees as operations progress.
• Raise additional funds for animal studies, efficacy experiments, and toxicology/pharmacokinetics studies needed for IND applications.
• Implement processes to document and retain evidence to support reviews and reconciliations to address material weaknesses in internal accounting controls.

Key Dates

Recommendation

The company's financial position is extremely precarious, with only $1 in cash, a rapidly increasing accumulated deficit, and negative working capital. It is entirely dependent on its parent company, BriaCell, for financing and explicitly states that current resources are insufficient for the next 12 months, necessitating a capital raise. This situation casts significant doubt on its ability to continue as a going concern. While the pre-clinical programs are promising and leverage AI, their advancement to human clinical trials is explicitly "pending funding" or "when funding is available," indicating substantial delays and uncertainty. The extensive list of risks, including dilution, reliance on third parties, unproven market, and lack of clinical data, further compounds the negative outlook. Given the severe liquidity issues, increasing losses, and high dependency on uncertain future financing, the stock represents a high-risk investment with a strong likelihood of further value erosion.

Keywords

BriaPro Therapeutics, BriaCell Therapeutics, Immuno-oncology, Biotechnology, Cancer Therapy, Bria-TILsRx, PKC Inhibitors, B7-H3 Antibodies, Artificial Intelligence Drug Discovery, Pre-clinical Development, SEC Filing, 8-K, Financial Statements, Research and Development, Going Concern, Capital Raise, Patent Application, Drug Development